Intravenous Immune Globulin in Neonatal ABO Isoimmunization: Factors Associated with Clinical Efficacy

Neonatology

Volumn 70, Issue 2, 1996, Pages 69-74

  Hammerman, Cathy ^a   Kaplan, Michael ^a   Vreman, Hendrik J ^b   Stevenson, David K ^b  

^a HEBREW UNIVERSITY   (Israel)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABO incompatibility; Carboxyhemoglobin; Coombs positive hemolytic anemia; Hemolysis; Intravenous immune globulin; Isoimmunization; Jaundice; Neonatal

Indexed keywords

BILIRUBIN; CARBOXYHEMOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN;

ARTICLE; BILIRUBIN BLOOD LEVEL; BIRTH WEIGHT; BLOOD GROUP ABO INCOMPATIBILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COOMBS TEST; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GESTATIONAL AGE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEWBORN; NEWBORN JAUNDICE; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT FAILURE;

ABO BLOOD-GROUP SYSTEM; BILIRUBIN; BLOOD GROUP ANTIGENS; CARBOXYHEMOGLOBIN; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; MALE; RH ISOIMMUNIZATION; TREATMENT OUTCOME;

EID: 0029740825     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000244350     Document Type: Article

References (12)

1. Sato K, Hara T, Kondo T, Iwao H, Honda S, Ueda K: High dose intravenous gammaglobulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility, Acta Pacdiatr Scand 1991;80: 163-166.
2. Rubo J, Albrecht K, Lasch P, Lauf-kotter E, Leititis J, Marsan D, Nei-mcyer B, Rocsler J, Roll C, Roth B, von Stockhausen H, Widemann B, Wahn V: High dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease, J Pediatr 1992;121:93-97.
3. Ergaz Z, Arad I: Intravenous immunoglobulin therapy in neonatal immune hemolytic jaundice, J Perinat Med 1993;21:183-187.
4. Vreman HJ, Stevenson DK, Zwart A: Analysis for carboxyhcmoglo-bin by gas chromatography and multicomponent spectrophotometry compared, Clin Chcm 1987;33: 694-697.
5. Vreman HJ, Mahoney JJ, Stevenson DK: Carbon monoxide and car-boxyhemoglobin, Adv Pediatr 1995; 42:303-334.
6. Ostrander CR, Cohen RS, Hopper AO, Cowan BE, Stevens GB, Stevenson DK: Paired determinations of blood carboxyhemoglobin concentrations and carbon monoxide excretion rate in term and preterm infants, J Lab Clin Med 1982; 100: 745-755.
7. Dufour DR, Monoghan WP: Hemolytic disease of the newborn, Am J Clin Pathol 1980;73:369-373.
8. Kirkman HN: Further evidence for a racial difference in frequency of ABO hemolytic disease, J Pediatr 1977;90:717-721.
9. Kaplan E, Herz F, Scheye E: ABO hemolytic disease of the newborn without hyperbilirubinemia, Am J Hematol 1976;1:279-282.
10. Graham H, Morrison M, McAn-drew R: A simple method for the prediction of ABO incompatibility using Sephadcx A-50, Vox Sang 1975;29:371-377.
11. Stevenson DK, Ostrander CR, Cohen RS, Johnson JD: Trace gas analysis in bilirubin metabolism: A technical review and current state of the art, Adv Pediatr 1982;29:129-149.
12. Brouwers HA, Overbeeke MA, van Ertbruggen I, Schaasberg W, Als-bach GP, Vander Hciden C, Van Leeuwen EF, Stoop JW, Engelfriet CP: What is the best predictor of the severity of ABO-haemolytic disease of the newborn? Lancet 1988:2: 641-644.